慢性阻塞性肺病藥物市場規模、佔有率及成長分析（依 COPD 類型、藥物類別、給藥途徑、病患屬性、通路和地區）：產業預測（2025-2032 年）

2023 年全球慢性阻塞性肺病藥物市場規模價值 75 億美元，預計將從 2024 年的 79.5 億美元成長到 2032 年的 126.7 億美元，預測期內（2025-2032 年）的複合年成長率為 6.0%。

全球慢性阻塞性肺病(COPD) 藥物市場正經歷顯著成長，這歸因於人們認知的提高、疾病患病率的上升以及對早期診斷和治療的日益重視。 COPD 是一種進行性呼吸系統疾病，主要由菸草煙霧和空氣污染等因素引起，且呈現快速成長趨勢，尤其是在都市區和開發中國家。這導致對增強肺功能和控制症狀的有效藥物的需求增加，有助於降低住院率。創新的聯合治療和先進的吸入技術正在獲得關注，進一步推動了市場擴張。此外，促進早期發現和意識提升的公共衛生舉措以及支持性政策正在推動這個市場的發展。隨著醫療保健系統優先考慮慢性病管理，COPD 藥物市場仍然是呼吸系統藥物中的一個重要組成部分。

目錄

介紹

• 分析目的
• 市場覆蓋
• 定義

分析方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 市場概況與展望
• 供需趨勢分析
• 按細分市場進行機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特分析

關鍵市場觀察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場魅力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

全球慢性阻塞性肺病藥物市場規模及依 COPD 類型分類的複合年成長率（2025-2032 年）

• 市場概覽
• 慢性支氣管炎
• 氣腫

全球慢性阻塞性肺病藥物市場規模及各藥物類別的複合年成長率（2025-2032）

• 市場概覽
• 聯合治療
• 支氣管擴張劑
• 皮質類固醇
• 磷酸二酯酶4抑制劑
• 黏液動力學
• 其他

全球慢性阻塞性肺病藥物市場規模及依給藥方式分類的複合年成長率（2025-2032）

• 市場概覽
• 吸入劑
• 口服
• 注射

以患者特徵分類的全球慢性阻塞性肺病藥物市場規模及複合年成長率（2025-2032 年）

• 市場概覽
• 年齡
• 性別
• 疾病嚴重程度

全球慢性阻塞性肺病藥物市場規模及按分銷管道分類的複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局

全球慢性阻塞性肺病治療藥物市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要企業採取的策略
• 近期市場趨勢
• 主要企業市場佔有率（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 年比收益比較（2022-2024 年）

主要企業簡介

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Ltd.
• CHIESI Farmaceutici SpA
• Cipla Inc.
• Exela Pharma Sciences LLC
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• Innoviva, Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Mundipharma International Ltd.
• Novartis AG
• Philip Morris International Inc.
• SHIONOGI Co. Ltd.
• Sumitomo Pharma Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Theravance Biopharma Inc.
• Vertex Pharmaceuticals Inc.
• Viatris Inc.

結論和建議

Global Chronic Obstructive Pulmonary Disease Drugs Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 7.95 billion in 2024 to USD 12.67 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global chronic obstructive pulmonary disease (COPD) drugs market is experiencing significant growth due to increasing awareness, rising disease prevalence, and a heightened focus on early diagnosis and treatment. COPD, a progressive respiratory condition primarily caused by factors such as cigarette smoke and air pollution, is escalating, particularly in urban areas and developing nations. As a result, the demand for effective pharmaceuticals that enhance lung function and manage symptoms is growing, contributing to reduced hospitalization rates. Innovative combination therapies and advanced inhalation technologies are gaining traction, further fueling market expansion. Additionally, public health initiatives promoting early detection and awareness, alongside supportive policies, are driving this market. As healthcare systems prioritize chronic disease management, the COPD drugs market remains a critical segment within respiratory therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Obstructive Pulmonary Disease Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Obstructive Pulmonary Disease Drugs Market Segments Analysis

Global Chronic Obstructive Pulmonary Disease Drugs Market is segmented by COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel and region. Based on COPD Type, the market is segmented into Chronic Bronchitis and Emphysema. Based on Drug Class, the market is segmented into Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics and Others. Based on Administration Type, the market is segmented into Inhalation Devices, Oral Medications and Injectable Formulations. Based on Patient Demographics, the market is segmented into Age, Gender and Disease Severity. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Obstructive Pulmonary Disease Drugs Market

The global market for chronic obstructive pulmonary disease (COPD) drugs is significantly influenced by the increasing prevalence of the condition, which affected approximately 212.3 million individuals worldwide in 2019 and resulted in 3.3 million deaths. In the United States, 6.6% of adults were diagnosed with COPD in 2018. The growing awareness of this disease, coupled with initiatives such as COPD Awareness Month, is anticipated to propel market growth by fostering early diagnosis and advancing treatment options. These efforts aim to enhance patients' quality of life, thereby driving demand for effective COPD medications globally.

Restraints in the Global Chronic Obstructive Pulmonary Disease Drugs Market

The global market for chronic obstructive pulmonary disease (COPD) drugs faces significant challenges due to various side effects associated with these medications. Adverse effects such as oral infections, bruising, and hoarseness can deter patient adherence and impede overall market growth. Although inhaled steroids, including Fluticasone, are effective in reducing the frequency of exacerbations, they can also heighten the risk of infections. Moreover, COPD drugs may lead to severe complications, such as depression, cardiovascular problems, pulmonary hypertension, and, in certain instances, lung cancer, which negatively affects patient outcomes and poses additional barriers for manufacturers in this sector.

Market Trends of the Global Chronic Obstructive Pulmonary Disease Drugs Market

The Global Chronic Obstructive Pulmonary Disease (COPD) Drugs market is witnessing a significant trend towards the emergence of biologics and personalized medicine. Innovative therapies like AstraZeneca's Fasenra are revolutionizing treatment approaches by precisely targeting the inflammation associated with COPD, thereby enhancing patient outcomes. This trend reflects a broader shift towards precision medicine, where treatments are tailored to individual patient profiles, reducing systemic side effects and improving efficacy. As awareness of COPD increases and the demand for effective management options rises, the integration of biologic therapies is expected to drive market growth and reshape therapeutic strategies globally in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by COPD Type & CAGR (2025-2032)

• Market Overview
• Chronic Bronchitis
• Emphysema

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Combination Therapy
• Bronchodilators
• Corticosteroids
• Phosphodiesterase Type 4 Inhibitor
• Mucokinetics
• Others

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Administration Type & CAGR (2025-2032)

• Market Overview
• Inhalation Devices
• Oral Medications
• Injectable Formulations

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Patient Demographics & CAGR (2025-2032)

• Market Overview
• Age
• Gender
• Disease Severity

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Chronic Obstructive Pulmonary Disease Drugs Market Size & CAGR (2025-2032)

• North America (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
  • US
  • Canada
• Europe (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CHIESI Farmaceutici SpA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exela Pharma Sciences LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innoviva, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck and Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mundipharma International Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philip Morris International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SHIONOGI Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations